Table 1 Overall characteristics of nAMD patients and control subjects

Number of cases

54

46

30

16

–

–

Age (years)

74.9 ± 7.5

77.0 ± 7.9

76.9 ± 8.6

77.1 ± 6.6

0.169

0.934

nAMD type (typical:PCV:RAP)

–

22:19:5

15: 2:3

7:7:2

–

0.914

Smoking (n, %)

16, 29.6

24, 52.2

16, 53.3

8, 50.0

0.023

0.829

HT (n, %)

30, 55.6

22, 47.8

18, 60.0

4, 25.0

0.446

0.009

DM (n, %)

4, 7.4

7, 15.2

6, 20.0

1, 6.2

0.230

0.216

d-ROMs (U. Carr)

387.6 ± 79.3

403.6 ± 70.6

393.8 ± 59.9

421.9 ± 86.5

0.290

0.259

BAP (μM/L)

2118.1 ± 212.6

2088.2 ± 289.2

2084.1 ± 229.5

2095.9 ± 386.0

0.564

0.912

SAF (AU)

2.0 ± 0.3

2.4 ± 0.5

2.3 ± 0.4

2.5 ± 0.5

 < 0.001

0.159

Initial anti-VEGF drug (IVR:IVA)

–

18:28

13:17

5:11

–

0.424

Cases that switched drug (n, %)

–

17, 37.0

11, 36.7

6, 37.5

–

0.956

Number of IVIs (one year)

–

5.6 ± 1.7

4.8 ± 1.6

7.1 ± 0.3

–

 < 0.001

VA (logMAR)

 Pre-treatment

–

0.40 ± 0.42

0.37 ± 0.41

0.47 ± 0.47

–

0.475

 One month later

–

0.38 ± 0.43

0.33 ± 0.40

0.49 ± 0.50

–

0.287

 One year later

–

0.36 ± 0.47

0.34 ± 0.51

0.40 ± 0.44

–

0.695

CMT (μm)

 Pre-treatment

–

342.0 ± 123.4

338.5 ± 134.9

348.5 ± 106.9

–

0.784

 One month later

–

246.4 ± 74.9

238.7 ± 63.5

260.4 ± 94.8

–

0.419

 One year later

–

245.3 ± 86.8

241.5 ± 66.1

252.3 ± 119.8

–

0.743